Adverse Effects Associated With Proton Pump Inhibitors

Adam J. Schoenfeld(Memorial Sloan Kettering Cancer Center), Deborah Grady(University of California, San Francisco)

JAMA Internal Medicine

January 11, 2016

10.1001/jamainternmed.2015.7927

Cited by 213

Related Papers

Acquired Resistance to Immune Checkpoint Inhibitors

|Cancer Cell|2020|927

Serum Lipoprotein Levels, Statin Use, and Cognitive Function in Older Women

|Archives of Neurology|2002|436

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib

|Annals of Oncology|2019|413

Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in <i>EGFR</i> -Mutant Lung Cancer

|Clinical Cancer Research|2020|381

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227

|Journal of Clinical Oncology|2022|375